13209-41-1

中文名称地塞米松EP杂质E

英文名称 Dexamethasone EP Impurity E

CAS 13209-41-1

分子式 C22H28O4

分子量 356.46

MOL 文件 13209-41-1.mol

更新日期 2025/05/14 14:22:57

13209-41-1 结构式

基本信息物理化学性质图谱信息常见问题列表

基本信息

中文别名

地塞米松杂质杂质E
地塞米松EP杂质E
糠酸莫米松杂质22
地塞米松磷酸钠杂质E
地塞米松杂质E(EP)
地塞米松磷酸钠杂质EP F
地塞米松磷酸钠杂质EP E
16Α-甲基-9,11-脱氢泼尼松龙

英文别名

Dexamethasone EP Imp E
Dexamethasone impurity E
Dexamethasone Impurity L
(8S,10S,13S,14S,16R,17R)-17-hydroxy
16α-Methyl-9,11-dehydro Prednisolone
Dexamethasone Impurity 5(Dexamethasone EP Impurity E)
17,21-dihydroxy-16alpha-methylpregna-1,4,9(11)-triene-3,20-dione
17, 21-dihydroxy-16α-methylpregna- 1, 4, 9(11)-triene-3,20-dione
(16α)-17,21-Dihydroxy-16-Methylpregna-1,4,9(11)-triene-3,20-dione
17.alpha.,21-Dihydroxy-16.alpha.-methylpregna-1,4,9(11)-triene-3,20-dione

所属类别

分析化学：药典标准品和杂质标准品

物理化学性质

熔点228-231 °C(Solv: acetone (67-64-1); hexane (110-54-3))

沸点548.3±50.0 °C(Predicted)

密度1.24±0.1 g/cm3(Predicted)

储存条件Refrigerator

溶解度氯仿（微溶）、二恶烷（微溶）、乙酸乙酯（微溶）

酸度系数(pKa)12.53±0.70(Predicted)

形态固体

颜色淡黄色

图谱信息

地塞米松EP杂质E(13209-41-1)核磁图(¹HNMR)

常见问题列表

生物活性

Vamorolone (VBP15) 是首创的，具有口服活性的解离性类固醇 (dissociative steroidal) 抗炎药和膜稳定剂。Vamorolone 改善肌营养不良，无副作用。Vamorolone 抑制 (NF-κB) 抑制作用，并降低了激素的影响。

体外研究

Vamorolone (VBP15) inhibits TNFα-induced pro-inflammatory NF-κB signaling in C2C12 muscle cells at 1 nM or more. Vamorolone binds the glucocorticoid receptor (GR) and mineralocorticoid receptor (MR) with similar affinity.
Vamorolone (0.1, 1μM; 30 minutes) reduces production of IL1βand CCL5 inflammatory mediators in primary human macrophages.
Vamorolone is a first-in-class mineralocorticoid receptor (MR) antagonist/dissociative glucocorticoid receptor (GR) ligand.

体内研究

Vamorolone (5-30 mg/kg; cherry syrup) shows a superior side effect profile compared to pharmacological glucocorticoids in mdx mice.
Vamorolone (30 mg/kg; orally; daily for 20 days) reduces CNS Inflammation in murine experimental autoimmune encephalomyelitis.

Animal Model:	C57BL/6 mice (experimental autoimmune encephalomyelitis)
Dosage:	30 mg/kg
Administration:	Orally; daily for 20 days (starting one day prior to MOG 33-55 peptide immunization and continuing)
Result:	Reduced CNS inflammation in murine experimental autoimmune encephalomyelitis.